Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

Go back to Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
(NYSE: RCUS) Delayed: 19.45 -4.3 (18.11%)
Previous Close $23.75    52 Week High $ 
Open $24.47    52 Week Low $ 
Day High $24.47    P/E N/A 
Day Low $19.27    EPS $ 
Volume 2,816,105